Comparative Pharmacology
Head-to-head clinical analysis: ENTADFI versus VARDENAFIL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENTADFI versus VARDENAFIL HYDROCHLORIDE.
ENTADFI vs VARDENAFIL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of a 5α-reductase inhibitor (finasteride) and a phosphodiesterase 5 inhibitor (tadalafil). Finasteride inhibits type II 5α-reductase, preventing conversion of testosterone to dihydrotestosterone, reducing prostate growth. Tadalafil inhibits PDE5, increasing cGMP in smooth muscle, causing relaxation of the prostate and bladder neck.
Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). It enhances the effect of nitric oxide (NO) by inhibiting PDE5, which is responsible for degradation of cGMP in the corpus cavernosum. This results in increased cGMP levels, leading to smooth muscle relaxation and increased blood flow to the corpus cavernosum, thereby facilitating penile erection.
5 mg orally once daily.
10 mg orally once daily as needed, approximately 60 minutes before sexual activity; maximum dose 20 mg; maximum frequency once daily.
None Documented
None Documented
Finasteride: terminal half-life ~6-8 hours (range 4-12 h) in young adults, 8 hours in elderly. Tadalafil: terminal half-life ~17.5 hours (range 11-28 h), supporting once-daily dosing.
Terminal elimination half-life is approximately 4-5 hours in healthy subjects. In elderly patients (≥65 years) or those with hepatic impairment (Child-Pugh A/B), half-life may be prolonged up to 6-8 hours.
ENTADFI (finasteride 5 mg and tadalafil 5 mg) is a fixed-dose combination. Finasteride is excreted 57% in feces (as metabolites) and 39% in urine (<1% as unchanged). Tadalafil is excreted primarily as metabolites, with 61% in feces and 36% in urine; <0.001% of dose is excreted unchanged in urine.
Primarily hepatic metabolism (CYP3A4, minor CYP2C9) followed by fecal excretion (approximately 91-95% of dose as metabolites) and renal excretion (approximately 2-6% as unchanged drug).
Category C
Category A/B
5-Alpha Reductase Inhibitor and PDE5 Inhibitor
PDE5 Inhibitor